Diagnosis and management of primary hyperparathyroidism

BMJ (Online)

Volumn 344, Issue 7849, 2012, Pages

  Pallan, Shelley ^a   Rahman, Mohammed Omair ^a   Khan, Aliya A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CINACALCET; CREATININE; ESTROGEN; LITHIUM; PARATHYROID HORMONE; PLACEBO; RALOXIFENE; THIAZIDE DIURETIC AGENT;

ADENOMA; AGE DISTRIBUTION; BONE DENSITY; BONE TURNOVER; CALCIUM HOMEOSTASIS; CALCIUM URINE LEVEL; DIFFERENTIAL DIAGNOSIS; DRUG ACTIVITY; DRUG EFFICACY; FAMILIAL DISEASE; FRAGILITY FRACTURE; HEAD AND NECK RADIATION; HORMONE PROTEIN COMPLEX; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPOCALCIURIA; MEDIASTINUM ADENOMA; MULTIGLANDULAR PARATHYROID HYPERPLASIA; MULTIPLE ENDOCRINE NEOPLASIA; NEPHROLITHIASIS; NONCALCEMIC HYPERPARATHYROIDISM; PARATHYROID CARCINOMA; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; PATIENT MONITORING; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREVALENCE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SIPPLE SYNDROME; SYMPTOMATOLOGY; THYMUS ADENOMA; TRACHEA TUMOR; TRACHEOESOPHAGEAL ADENOMA;

DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; HUMANS; HYPERPARATHYROIDISM, PRIMARY; PARATHYROIDECTOMY;

EID: 84858815708     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e1013     Document Type: Review

References (37)

1. Khan A, Bilezikian J. Primary hyperparathyroidism: pathophysiology and impact on bone. CMAJ 2000;163:184-7. (Pubitemid 30625659)
2. Khan AA, Bilezikian JP, Potts JT Jr. The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. J Clin Endocrinol Metab 2009;94:333-4.
3. Adami S, Marcococci C, Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res 2002;17(suppl 2):N18-23. (Pubitemid 35222308)
4. Phitayakorn R, McHenry CR. Incidence and location of ectopic abnormal parathyroid glands. Am J Surg 2006;191:418-23. (Pubitemid 43266018)
5. Eastell R, Arnold A, Brandi ML, Brown EM, D'Amour P, Hanley DA, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009;94:340-50.
6. Tfelt-Hansen J, Brown EM. The calcium-sensing receptor in normal physiology and pathophysiology: a review. Crit Rev Clin Lab Sci 2005;42:35-70. (Pubitemid 41656709)
7. Wermers RA, Kearns AE, Jenkins GD, Melton LJ 3rd. Incidence and clinical spectrum of thiazide-associated hypercalcemia. Am J Med 2007;120:911.e9-15.
8. Haden ST, Stoll AT, McCormick S, Scott J, Fuleihan G el-H. Alterations in parathyroid hormone dynamics in lithium-treated subjects. J Clin Endocrinol Metab 1997;82:2844-8. (Pubitemid 27385637)
9. Beard CM, Heath H III, O'Fallon WM, Anderson JA, Earle JD, Melton LJ 3rd. Therapeutic radiation and hyperparathyroidism: a case-control study in Rochester, Minn. Arch Intern Med 1989;149:1887-90. (Pubitemid 19200850)
10. Schneider AB, Gierlowski TC, Shore-Freedman E, Stovall M, Ron E, Lubin J. Dose-response relationships for radiation-induced hyperparathyroidism. J Clin Endocrinol Metab 1995;80:254-7.
11. Khan AA, Hanley DA, O'Brien CJM, Pasieka J, Ste-Marie LG, Rotstein LE, et al. Canadian position paper. Asymptomatic primary hyperparathyroidism: standards and guidelines for diagnosis and management in Canada. Endocr Pract 2003;9(5).
12. Rubin MR, Silverberg SJ. Rheumatic manifestations of primary hyperparathyroidism and parathyroid hormone therapy. Curr Rheumatol Rep 2002;4:179-85.
13. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009;94:351-65.
14. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007;92:3001-5. (Pubitemid 47236362)
15. Al-Azem H, Khan AA. Primary hyperparathyroidism. CMAJ 2011;183:E685-9.
16. Udelsman R, Pasieka J Sturgeon C, Young JCM, Clark O. Surgery for asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2009;94:366-72.
17. Starker LF, Fonseca AL, Carling T, Udelsman R. Minimally invasive parathyroidectomy. Int J Endocrinol 2011;2011:206502.
18. Cheung K, Wang TS, Farrokhyar F, Roman SA, Sosa JA. A meta-analysis of preoperative localization techniques for patients with primary hyperparathyroidism. Ann Surg Oncol 2012;19:577-83.
19. Bilezikian JP, Khan AA, Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009;94:335-9.
20. Bollerslev J, Jansson S, Mollerup CL, Nordenström J, Lundgren E, Toørring O, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 2007;92:1687-92.
21. Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2004;89:5415-22. (Pubitemid 39518419)
22. Morris GS, Grubbs EG, Hearon CM, Gantela S, Lee JE, Evans DB, et al. Parathyroidectomy improves functional capacity in "asymptomatic" older patients with primary hyperparathyroidism: a randomized control trial. Ann Surg 2010;251:832-7.
23. Mollerup CL, Vestergaard P, Frøkjaer VG, Mosekilde L, Christiansen P, Blichert-Toft M. Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. BMJ 2002;325:807.
24. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999;341:1249-55. (Pubitemid 29489739)
25. Vignali E, Viccica G, Diacinti D, Cetani F, Cianferotti L, Ambrogini E, et al. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2009;94:2306-12.
26. Ambrogini E, Cetani F, Cianferotti L, Vignali E, Banti C, Viccica G, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 2007;92:3114-21. (Pubitemid 47236379)
27. VanderWalde LH, Liu IL, Haigh PI. Effect of bone mineral density and parathyroidectomy on fracture risk in primary hyperparathyroidism. World J Surg 2009;33:406-11.
28. Sankaran S, Gamble G, Bolland M, Reid IR, Grey A. Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis. J Clin Endocrinol Metab 2010;95:1653-62.
29. Stefenelli T, Abela C, Frank H, Koller-Strametz J, Globits S, Bergler-Klein J, et al. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocrinol Metab 1997;82:106-12. (Pubitemid 27021279)
30. Bollerslev J, Rosen T, Mollerup CL, Nordenström J, Baranowski M, Franco C, et al SIPH Study Group. Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2009;94:2255-61.
31. Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 2001;16:113-9. (Pubitemid 32046195)
32. Chow CC, Chan WB, Li JK, Chan NN, Chan MH, Ko GT, et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:581-7. (Pubitemid 36207794)
33. Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:3319-25. (Pubitemid 38951898)
34. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med 1996;125:360-8. (Pubitemid 126449705)
35. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:1174-8. (Pubitemid 36337773)
36. Khan A, Grey A, Shoback D. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009;94:373-81.
37. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90:135-41. (Pubitemid 40116646)